MENU
IMTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Immatics (IMTX) Earnings Date & Reports
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more
A.I. Advisor
published Earnings
IMTX is expected to report earnings to fall 1.42% to -42 cents per share on August 19
Q2'26
Est.
$-0.42
Q1'26
Missed
by $0.04
Q4'25
Beat
by $0.13
Q3'25
Missed
by $0.04
Q2'25
Missed
by $0.28
The last earnings report on May 12 showed earnings per share of -43 cents, missing the estimate of -39 cents. With 163.45K shares outstanding, the current market capitalization sits at 1.29B.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
Industry Biotechnology
Profile
Details
Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
711
Web
https://www.immatics.com